Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in Type 2 diabetes mellitus complicated by retinopathy

Diabetic Medicine

Volumn 16, Issue 6, 1999, Pages 514-521

  Garpenstrand, H ^a   Ekblom, J ^a   Backlund L B ^b   Oreland, Lars ^a   Rosenqvist, U ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b ST ERIK S EYE HOSPITAL   (Sweden)

Author keywords

Glycated haemoglobin A; Photography; Primary health care; Semicarbazide sensitive amine oxidase (SSAO); Sweden

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; SEMICARBAZIDE DERIVATIVE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE DURATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PRIMARY HEALTH CARE; RETINOPATHY;

AMINE OXIDASE (COPPER-CONTAINING); BENZYLAMINES; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED;

EID: 0032750158     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00103.x     Document Type: Article

References (47)

1. 1 Klein R, Klein BE. Diabetic eye disease. Lancet 1997; 350: 197-204.
2. 2 Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL 3rd et al. Diabetic retinopathy. Diabetes Care 1998; 21: 143-156.
3. 3 Reichard P, Nilsson B-Y, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes. N Engl J Med 1993; 329: 304-309.
4. 4 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
5. 5 The Diabetes Control and Complications Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
6. 6 Lewinsohn R. Mammalian monoamine-oxidizing enzymes, with special reference to benzylamine oxidase in human tissues. Brazilian J Med Biol Res 1984; 17: 223-256.
7. 7 Boomsma F, Derkx FHM, van den Meiracker AH. Man in't Veld AJ, Schalekamp MADH. Plasma semicarbazide-sensitive amine oxidase activity is elevated in diabetes mellitus and correlates with glycosylated haemoglobin. Clin Sci 1995; 88: 675-679.
8. 8 Yu PH, Zuo DM. Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications. Diabetologia 1997; 40: 1243-1250.
9. 9 Ekblom J. Potential therapeutic value of drugs inhibiting semicarbazide-sensitive amine oxidase: vascular cytoprotection in diabetes mellitus. Pharmacol Res 1998; 37: 87-92.
10. 10 Nicholls R, de Jersey J, Worrall S, Wilce P. Modification of proteins and other biological molecules by acetaldehyde: adduct structure and functional significance. Int J Biochem 1992; 24: 1899-1906.
11. 11 Kinyoun JL, Martin DC, Fujimoto WY, Leonetti DL. Ophthalmoscopy versus fundus photographs for detecting and grading diabetic retinopathy. Invest Ophtalmol Vis Sci 1992; 33: 1888-1893.
12. 11 Retinopathy Working Party (Kohner EM, Porta M). A protocol for screening for diabetic retinopathy in Europe. Diabetic Med 1991; 8: 263-267.
13. 13 Kuiv R, Tein P, Algvere PV, Bäcklund LB, Holm O. Photographic detection of retinopathy in insulin-treated diabetes. A population study in the city of Tartu, Estonia. Acta Ophthalmol Scand 1997; 75: 447-156.
14. 14 Bäklund LB, Algvere PV, Rosenqvist U. Early detection of diabetic retinopathy by a mobile retinal photography service working in partnership with primary health care teams. Diabetic Med 1998; 15: S32-S37.
15. 15 Aldington SJ, Kohner EM, Meuer S, Klein K, Sjolie AK. Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM Complications Study. Diabetologia 1995; 38: 437-444.
16. 16 Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification. ETDRS Report Number 10. Ophthalmology 1991; 98: 786-806.
17. 17 Eckerbom S, Bergqvist Y. Improved sample collection technique for capillary blood on filter paper for determination of glycated haemoglobin. Ann Clin Biochem 1989; 26: 148-150.
18. 1c.: eight years experience. Diabetic Med 1997; 14: 401-403.
19. 19 Eckerhom S, Bergqvist Y, Jeppsson J-O. Improved method for analysis of glycated haemoglobin by ion exchange chromatography. Ann Clin Biochem 1994; 31: 355-360.
20. 1c based on peptide mapping. Clin Chem 1997; 43: 1944-1951.
21. 21 Kullberg CE, Bergström A, Dinesen R, Larsson L, Little LL, Goldstein DE et al. Comparisons of studies on diabetic complications hampered by differences in GHb measurements. Diabetes Care 1996; 19: 726-729.
22. 22 McCaman RE, McCaman MW, Hunt JM, Smith MS. Microdetermination of monoamme oxidase and 5-hydroxytryptophan decarboxylase activities in nervous tissues. J Neurochem 1965; 12: 15-23.
23. 23 Israel Y, MacDonald A, Niemelä O, Zamel D, Shami E, Zywulko M et al. Hypersensitivity to acetaldehyde-protein adducts. Mol Pharmacol 1992; 42: 711-717.
24. 24 McEwen CM, Harrison DC. Abnormalities of serum monoamine oxidase in chronic congestive heart failure. J Lab Clin Med 1965; 65: 546-559.
25. 25 Boomsma F, van Veldhuisen DJ, de Kam PJ, Man in 't Veld AJ, Mosterd A, Lie KI et al. Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. Cardiovasc Res 1997; 33: 387-391.
26. 26 McEwen CM Jr, Castell DO. Abnormalities of serum monoamine oxidase in chronic liver disease. J Lab Clin Med 1967; 70: 36-47.
27. 27 Buffoni E, Ignesti G, Pirisino R, Cortesini C. Platelet monoamine oxidase, plasma benzylamine oxidase and liver mixed function oxidase in cirrhotic patients. Med Biol 1977; 55: 109-111.
28. 28 Nilsson SE, Tryding N, Tufvesson G. Serum monoamine oxidase (MAO) in diabetes mellitus and some other internal diseases. Acta Med Scand 1968; 184: 105-108.
29. 29 Hayes BE, Clarke DE. Semicarbazide-sensitive amine oxidase activity in streptozotocin diabetic rats. Res Commun Chem Pathol Pharmacol 1990; 69: 71-83.
30. 30 Elliott J, Fowden AL, Callingham BA, Sharman DF, Silver M. Physiological and pathological influences on sheep blood plasma amine oxidase: effect of pregnancy and experimental alloxaninduced diabetes mellitus. Res Vet Sci 1991; 50: 334-339.
31. 31 Precious E, Gunn CE, Lyles GA. Deamination of methylamine by semicarbazide-sensitive amine oxidase in human umbilical artery and rat aorta. Biochem Pharmacol 1988; 37: 707-713.
32. 32 Lyles GA, Chalmers J. The metabolism of aminoacetone to methylglyoxal by semicarbazide-sensitive amine oxidase in human umbilical artery. Biochem Pharmacol 1992; 43: 1409-1414.
33. 33 Yu PH. Deamination of methylamine and angiopathy; toxicity of formaldehyde, oxidative stress and relevance to protein glycoxidation in diabetes. J Neural Transm Suppl 1998; 52: 201 -216.
34. 34 Yu PH, Zup DM. Oxidative deamination of methylamine by semicarbazide-sensitive amine oxidase leads to cytotoxic damage in endothelial cells. Diabetes 1993; 42: 594-603.
35. 35 McLellan AC, Thornalley PJ, Benn J, Sönksen PH. Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci 1994; 87: 21-29.
36. 36 Lyles GA, Singh I. Vascular smooth muscle cell: a major source of the semicarbazide-sensitive amine oxidase of the rat aorta. J Pharm Pharmacol 1985; 37: 637-643.
37. 37 Wibo M, Duong AT, Godfraind T. Subcellular location of semicarbazide-sensitive amine oxidase in rat aorta. Eur J Biochem 1980; 112: 87-94.
38. 38 Enrique-Tarancon G, Marti L, Morin N, Lizcano JM, Unzeta M, Sevilla I. et al. Role of semicarbazide-sensitive amine oxidase on glucose transport and GLUT4 recruitment to the cell surface in adipose cells. J Biol Chem 1998; 273: 8025-8032.
39. 39 Yu PH, Zuo DM, Davis BA. Characterization of human serum and umbilical artery semicarbazide-sensitive amine oxidase (SSAO). Biochem Pharmacol 1994; 47: 1055-1059.
40. 40 Heck HA, Casanova M, Starr TB. Formaldehyde toxicity - new understanding. Toxicology 1990; 20: 397-426.
41. 41 Pietrznk ER, Shanley BC, Kroon PA. Antibodies made against a formaldehyde-protein adduct cross react with an acetaldehyde-protein adduct. Implications for the origin of antibodies in human serum which recognize acetaldehyde protein adducts. Alcohol Alcohol 1995; 30: 373-378.
42. 42 Barry RE, McGivan JD. Acetaldehyde alone may initiate hepatocellular damage in acute alcoholic liver disease. Gut 1985; 26: 1065-1069.
43. 43 Lynen R, Rothe M, Gallasch E. Characterization of formaldehyderelated antibodies encountered in hemodialysis patients at different stages of immunization. Vox Sang 1983; 44: 81-89.
44. 44 Thornalley PJ. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification - a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 1996; 27: 565-573.
45. 45 Callingham BA, Crosbic AE, Rous BA. Some aspects of the pathophysiology of semicarbazide-sensitive amine oxidase enzymes. Prog Brain Res 1995; 106: 305-321.
46. 46 Lyons T, Jenkins AJ. Glycation, oxidation and lipoxidation in the development of the complications of diabetes mellitus: a 'carbonyl stress' hypothesis. Diabetes Rev 1997; 5: 365-391.
47. 47 Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-866.